ID
DB10601||
名称
Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated)
描述
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to. There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.
cas号
唯一标识码
5087BPO79O
状态
一般参考文献


approved,
指示
药效学
作用机制
毒性
代谢
吸收
半衰期
分类
消除途径
种类
盐类
蛋白质结合
清除
同义词
language:english; code:; name;influenza A virus A/South Australia/55/2014 (H3N2) antigen
国际品牌
配送量
产品
name:Afluria
labeller:bioCSL Pty Ltd.
ndc-id:
ndc-product-code:33332-115
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-07-15
ended-marketing-on:2016-06-30
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA125254
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Afluria
labeller:bioCSL Pty Ltd.
ndc-id:
ndc-product-code:33332-015
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-07-15
ended-marketing-on:2016-06-30
dosage-form:Injection, suspension
strength:
route:Intramuscular
fda-application-number:BLA125254
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
混合物
name:Afluria
ingredients:Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) + Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated) + Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated)
name:Afluria
ingredients:Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) + Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated) + Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated)
包装者
生产者
价格
受影响的生物体
剂量
form:Injection, suspension
route:Intramuscular
strength:
atc代码
fda标签
化学品安全技术说明书
专利
食物相互作用
药物相互作用
序列
实验性质
外部标识符
resource:RxCUI
identifier:1657130
外部链接
路径
目标
载体
运输工具
药物反应
效应
不良反应